Despite international guidelines, optimal delivery models of late effects (LE) services for HSCT patients are unclear from the clinical, organizational and economic viewpoints. To scope current LE service delivery models within the UK NHS (National Health Service), in 2014, we surveyed the 27 adult allogeneic HSCT centres using a 30-question online tool, achieving a 100% response rate. Most LE services were led and delivered by senior physicians (480% centres). Follow-up was usually provided in a dedicated allograft or LE clinic for the first year (490% centres), but thereafter attrition meant that only~50% of patients were followed after 5 years. Most centres (69%) had a standard operating procedure for long-term monitoring but access to a LE Multi-Disciplinary Team was rare (19% centres). Access to medical specialities necessary for LE management was good, but specialist interest in long-term HSCT complications was uncommon. Some screening (endocrinopathy, cardiovascular) was near universal, but other areas were more limited (mammography, cervical smears). Funding of extra staff and investigations were the most commonly perceived barriers to implementation of LE services. This survey shows variation in the long-term follow-up of allogeneic HSCT survivors within the UK NHS and further work is warranted to optimize effective, sustainable and affordable models of LE service delivery among this group.
INTRODUCTION
Since the first recorded allogeneic haematopoietic stem cell transplant (HSCT) using a donor other than an identical twin in 1968, 1 the worldwide annual number of patients undergoing this procedure has risen to more than 23 500. 2 Over the same period, improvements in conditioning regimens 3 (for example, reduced intensity conditioning) and supportive care (for example, management of infectious complications 4, 5 and GvHD), 6 as well as widening of indications to include non-malignant disorders (for example, haemoglobinopathies) 7 and availability of alternative HSCT donors 8 have led to increasing numbers of long-term survivors (that is, alive 2 years post allogeneic HSCT). 9 However, with improved survival, even in the absence of disease relapse, normal life expectancy is not restored. 10 Survivors are susceptible to organ dysfunction 11, 12 (aside from chronic GvHD) and subsequent malignancies 13 resulting in a significant morbidity burden 14 and premature mortality. In addition to physical sequelae, allogeneic HSCT survivors are at risk of psychological complications, including post-traumatic stress disorder, 15 which may have a major impact on quality of life. 16 The increased morbidity and non-relapse mortality exhibited by long-term allogeneic HSCT survivors led to recognition of the need for long-term follow-up and screening of this patient population to allow pre-emptive action to try to mitigate the increased risks. Accordingly, the Center for International Blood and Marrow Transplant Research, European Group for Blood and Marrow Transplantation and American Society for Blood and Marrow Transplantation produced consensus recommendations on the subject in 2006 (ref. 17 ; subsequently enshrined in JACIE (sixth edition) standard B7.6.8). 18 These were updated in 2011 with additional representation from the Asia-Pacific Blood and Marrow Transplantation Group, Bone Marrow Transplant Society of Australia and New Zealand, East Mediterranean Blood and Marrow Transplantation Group and Sociedade Brasileira de Transplante de Medula Ossea to ensure their international applicability. 19 Owing to lack of prospective (randomized) controlled trials in this area, these are based on retrospective studies, non-transplant data and expert consensus opinion, but nevertheless are considered to be the most comprehensive guidance available for management of this patient population.
However, there is little consensus on how the international guidelines are best applied and data are limited as to the extent of their implementation. 20, 21 On behalf of the British Society of Blood and Marrow Transplantation (BSBMT), we sought to establish how services for late post-transplant effects were delivered by UK adult allogeneic HSCT centres within the governmentally funded 1 National Health Service (NHS). Although ultimately all NHS services are state funded, HSCT procedures are nationally commissioned while care from day 100 post transplant is locally commissioned. 22 
MATERIALS AND METHODS

Survey development and design
A 30-question web-based survey was developed following consultation with senior UK allogeneic HSCT physicians and nurses with an interest in late effects (LE) services for allogeneic HSCT survivors and representatives of organizations concerned with allogeneic HSCT patient welfare (for example, Anthony Nolan). The questions were designed around four themes; service organization, access to other specialist services necessary for the management of LE, multi-disciplinary team (MDT) provision and patient engagement, service evaluation and improvement. Most questions required respondents to select one/several options from a range of possibilities although, where relevant, there was the ability to enter free text. The survey was piloted with members of the BSBMT-Clinical Trials Committee before wider circulation.
For the purposes of this survey, the National Cancer Institute definition of LE was used: 'A health problem that occurs months or years after a disease is diagnosed or after treatment has ended. Late effects may be caused by cancer or cancer treatment. They may include physical, mental and social problems and second cancers' (http://www.cancer.gov/diction ary?cdrid=390292). The definition was extended to patients with nonmalignant diseases who had been treated with allogeneic transplantation, where LE may be caused by the disease or disease treatment. In several questions, respondents were asked to provide the percentage of patients in whom a particular activity took place; this was intended to be a best estimate for surviving patients at that time point rather than an exact calculated figure. The survey is available in the Supplementary Information.
Survey administration
The survey was circulated via the BSBMT to programme directors of the 27 adult UK NHS allogeneic HSCT centres with an invitation for the most appropriate personnel to complete (medical or nursing). One generic reminder was sent to all centres after which individual approaches were made by the survey authors to non-responding centres. The survey was completed during the year 2014. Statistical associations between overall allogeneic HSCT centre activity, co-existent paediatric HSCT activity in the centre and the long-term follow-up patterns were explored using 2014 activity data from the BSBMT registry. 23 
RESULTS
Centre demographics
A 100% response rate was achieved, with most surveys (85%) completed by allogeneic HSCT physicians (Table 1) : Although all centres (27) submitted a response to the survey, some centres omitted to answer particular questions -results from these questions are reported as percentages of the responding centres, with the number of responses used indicated by n = x. All centres were engaged with the JACIE accreditation process; 82% were fully accredited (Table 1) having completed a median of two accreditation cycles. The lower age of allogeneic HSCT recipients ranged from 16 to 20 years (Table 1 ) with almost half of adult centres (46%) performing allogeneic HSCT in patients under 18 years of age (both the European Group for Blood and Marrow Transplantation and UK legal definition of an adult).
LE service organization
The LE service was most frequently organized and administered by medically qualified staff (88% centres) with the remainder being nurse led (Table 1) . Most LE services were delivered in either a dedicated clinic (63%) or within the general allogeneic HSCT clinic (33%) with only one centre routinely reviewing patients in a general haematology clinic (Table 1 ). Figure 1a shows there was an attrition rate over time in the percentage of surviving postallogeneic HSCT patients being followed up by the transplanting The LE SOP could be based on both physical and psychological assessments. Refers to percentages calculated with denominators other than 27 (that is, the total population surveyed); used when answering a question was conditional upon an affirmative response to a preceding question.
centre. Although 96% of centres followed up all patients from day 100 to 1 year, by 5 years post allogeneic HSCT, only 48% centres routinely reviewed all patients and 11% of centres were actively following up fewer than half their patients. In some centres, part of this attrition was due to formal discharge of patients at 5 years post allogeneic HSCT back to either their referring non-HSCTperforming haematology centre or primary care physician if they had received a reduced intensity conditioning HSCT and were free of complications including GvHD. Other patients, however, were lost to follow-up (for example, moved away geographically from the transplanting centre). Centre size and co-existent paediatric activity were not significantly associated with long-term follow-up patterns for adults (see Supplementary Table 1) .
A standard operating procedure for long-term monitoring of LE (as indicated by JACIE (sixth edition) standard B7.6.8) 18 was available in 69% of responding allogeneic HSCT centres (n = 26), with 39% of these centres having audited their adherence to the policy (Table 1 ). All standard operating procedures included the physical assessment of patients but only 28% made any reference to psychological evaluation ( Table 1) . The use of a standard template to communicate treatment summaries and potential complications to other healthcare professionals (as recommended by the National Cancer Survivorship Initiative; example template available at http://www.ncsi.org.uk/wp-content/uploads/Treat ment-Summary-Template1.doc) was undertaken in 41% of centres (Table 1) .
Access to specialist services Figure 1b illustrates the range of specialist services available to allogeneic HSCT centres (n = 26) in the management of LE. All the medical specialities were accessible to 480% of responding centres. Easiest access was reported to endocrinology, sexual health and respiratory services (96, 93 and 93% centres, respectively), whereas more limited, but still good, access was available for oral medicine and dentistry services (81% centres). Access to allied health specialities was more varied: although most centres (89%) had access to a dietician, availability of physiotherapy, occupational therapy and psychology support was not universal with only 62%, 65% and 69% of centres being able to access these, respectively.
In contrast to the overall good access to specialist services for allogeneic HSCT survivors, the number of centres reporting personnel in these specialities with an interest in the LE of Respondents were asked to rate potential barriers on a numerical scale from 0 to 10 where 0 represents no barrier, whereas 10 is a major barrier to implementation.
allogeneic HSCT was low (Figure 1b) . With the exception of key workers and clinical nurse specialists, the majority of whom had an interest in HSCT LE as might be expected (94% and 84%, respectively), fewer than 50% of centres reported personnel with a specialist interest among any medical or allied health speciality. Greatest interest was seen in specialities likely to have the most contact with post-HSCT patients; endocrinology, dietetics, sexual health and respiratory medicine (46%, 39%, 39% and 35%, respectively).
Respondents reported variable compliance with screening recommendations in the international guidelines. 19 Although routine rates of implementation of endocrine and cardiovascular screening were good (89% and 78%, respectively), lower rates of cervical screening and mammography were reported (52% and 48%, respectively) despite the existence of established National Breast 24 and Cervical Cancer 25 Screening Programmes within the UK for the general population (Table 1 ). Only 30% of centres found it easy to access these National Screening Programmes.
There was near universal implementation of re-vaccination post allogeneic HSCT (96% centres) although only 23% of centres undertook antibody testing in the majority of patients (490%) to monitor vaccine efficacy (Table 1) . Among the remainder of centres, there was variation in post-vaccine antibody response monitoring; some never undertook such testing while others targeted it to patients with recurrent infections or those felt to have a particularly high infection risk (for example, HLA mismatch, alternative stem cell donor source). Post-allogenic HSCT vaccination practice has been the subject of a separate more detailed BSBMT survey. 26 MDT provision Only 19% of centres had access to a specific LE MDT (Table 1) and where available this was mostly (60% MDTs) limited to patients under 25 years (data not shown). Where LE MDTs were available, membership varied: although all included a senior haematologist and clinical nurse specialist, there was less regular support from other speciality physicians (including paediatrics), psychologists and social workers.
Patient engagement, service evaluation and improvement A patient support group whose target audience included long-term allogeneic HSCT survivors was available in 41% of centres (Table 1) variably led by nurses, social workers, psychologists or patients themselves. Where available, most (73%) met at least every 3 months (data not shown). Given a central theme of JACIE standards relates to education, service evaluation and audit to bring about service improvement, centres were asked how often they engaged in such activities that included some aspect of LE monitoring or care. At least one formal educational event covering an aspect of LE management had been delivered by 67% of centres in the preceding three years, while a clinical audit or service evaluation had been performed by 59% of centres (n = 26) over the same period. However, only 41% of centres had sought patient input regarding their satisfaction with LE and long-term follow-up arrangements over this time (Figure 1c ).
During consultations with relevant stakeholders before development of this survey, it became apparent there were a number of differences between the realities of the LE services provided by allogeneic HSCT centres and what they felt should be available. To ascertain the impediments to LE service delivery, centres rated potential barriers to implementation of an idealized service (suggested both by the survey authors and in the literature). 27 These are summarized in Figure 1d , and the three highest rated obstacles all relate to finance/resource provision, with lack of funding for psychological support considered to be the greatest limitation. DISCUSSION To our knowledge, this is the first survey examining the practical provision of long-term follow-up and LE services for allogeneic HSCT patients across a national healthcare system. It provides a comprehensive view of how care is being delivered to this complex patient population. Despite national publically funded delivery of HSCT care, the survey demonstrates variability in almost every aspect of the service. Some variation may reflect the historical, opportunistic way LE services have evolved in individual centres. Although we were unable to show any relationship with centre activity and co-existent paediatric activity, other factors such as centre specialization, geography and referral base may be contributory and further work is required in this area.
This survey highlighted some positives in that all centres had an LE service and most had a standard operating procedure outlining its processes. In addition, most centres reported good local availability of a range of medical and some allied health specialities necessary for the management of LEs. Free text comments indicated many centres are engaged in active development of their LE service through the appointment of new personnel and by establishing separate clinics (in some cases, combined with cGvHD management).
However, this survey also emphasized general weaknesses and limitations of LE services throughout the UK, including limited access to LE MDTs. Despite good provision of most other specialities necessary for the management of LE within tertiary NHS hospitals, most specialists delivering this care did not have a particular interest in post-allogeneic HSCT care. Although national screening programmes exist for both breast 24 and cervical cancer 25 detection, enrolling post-allogeneic HSCT patients in these outside of standard age-dictated times was problematic. Both these points highlight a need for better engagement and education of healthcare professionals outside of haematology. 21, 28 This survey also demonstrates a bias of LE services towards screening activities within the normal remit of transplant physicians and associated personnel. Assessment of endocrine and cardiovascular function was generally carried out well while in contrast, implementation of specialized services where transplant physicians have less control (for example, mammography, cervical screening) was much poorer. In common with other post-HSCT populations, 29 there was limited access to specialist psychological services in this susceptible population. 15 Only 28% of LE standard operating procedures had any reference to psychological function despite international guidelines and recommendations. 19 The emphasis of many LE services on the management of medical symptoms may not always correlate with patient concerns. A recent audit of patient-reported symptoms in a nurse-led post-HSCT LE clinic indicated that the most prevalent problems were pain, sleep disturbance, fatigue and sexual function concerns, 30 none of which are easily attributable to a particular physiological system. The apparent misalignment of the LE service agenda 31 and patient concerns 32 is something that could be addressed by better engagement of patients through support groups and quality of life 33 or service satisfaction surveys. 34 Ultimately patient interests are likely to be best served with long-term follow-up LE services led and delivered by a combination of medical and nursing staff with the flexibility for patients to be seen by either group of healthcare professionals depending on their specific symptoms and needs. Perhaps, as expected, all allogeneic HSCT centres identified lack of financial resources as the major constraint on the implementation of ideal services, particularly regarding the delivery of psychological support.
As with any survey, it is necessary to exercise some caution with result interpretation. First, centres can only report activities over which they have direct control. The survey suggests that patients from only 30% of centres undergo lifelong follow-up (that is, beyond 10 years) as recommended by international guidelines. 19 However, it is possible that many of the remaining 70% of centres refer patients back to either their referring hospital or primary care provider to follow a recommended LE surveillance plan; activity which would not necessarily be known to the transplanting centre.
Second, the results inevitably reflect what a centre reports to be doing rather than what has been independently verified as taking place. Nevertheless, given the deficiencies in the LE service reported by almost all centres, it seems likely that the responses represent a consistent summary of service provision and operation. Finally, although this survey documents variation in practice, it does not provide information about how this affects patient outcome. To optimize long-term follow-up and LE service provision, it is necessary to collect data on patient outcomes with the different models of care delivery.
In summary, this survey provides valuable feedback on the current delivery of LE service provision for post-allogeneic HSCT survivors within the UK, which is likely to be applicable to other healthcare systems internationally. It provides information about where international guidelines and recommendations 19 are being easily met and areas where services are deficient and require additional resource investment. Further research into which models of care provide the most clinically effective and cost-efficient means of service delivery is warranted.
